Yahong Medicine Signs Exclusive License Agreement with Theramex

Yahong Medicine announced that the company has entered into a conditional exclusive license agreement with Theramex. Under the terms of the agreement, Theramex will receive exclusive rights to APL-1702 (brand name: CEVIRA®/希维她®) in European countries, as well as Australia, New Zealand, and Turkey, while the company retains rights for all other global regions. For this transaction, Yahong Medicine will receive an upfront payment of $15 million, near-registration milestone payments of $11 million, commercialization milestone payments, and tiered sales royalties, with total deal value exceeding $250 million.